Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Nov 28, 2018; 24(44): 5046-5056
Published online Nov 28, 2018. doi: 10.3748/wjg.v24.i44.5046
Figure 2
Figure 2 Kaplan-Meier survival curves of high and normal groups of different indicators in 170 resected primary gastrointestinal stromal tumor patients. (A) Fibrinogen (FIB) category; (B) D-dimer category; (C) D-dimer-fibrinogen ratio (DFR) category; (D) Platelet (PLT) category; (E) Adjuvant imatinib treatment of intermediate and high risk gastrointestinal stromal tumor patients. RFS was significantly lower for each variable in the high group than in the low group (P < 0.05). FIB: Fibrinogen; DFR: D-dimer-fibrinogen ratio; RFS: Recurrence-free survival; GIST: Gastrointestinal stromal tumor.